N6-Methyladenosine modification: a novel pharmacological target for anti-cancer drug development
Authors:
Open Access
- 1 October 2018
- journal article
- review article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 8 (6) , 833-843
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (31701114)
- Fundamental Research Funds for University-Key Cultivation Project of Young Teacher in Sun Yat-Sen University (17ykzd11)
This publication has 106 references indexed in Scilit:
- The oncoprotein HBXIP activates transcriptional coregulatory protein LMO4 via Sp1 to promote proliferation of breast cancer cellsCarcinogenesis, 2013
- ALKBH5 Is a Mammalian RNA Demethylase that Impacts RNA Metabolism and Mouse FertilityMolecular Cell, 2013
- MODOMICS: a database of RNA modification pathways—2013 updateNucleic Acids Research, 2012
- Target mRNA inhibition by oligonucleotide drugs in manNucleic Acids Research, 2012
- Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop CodonsCell, 2012
- MYC on the Path to CancerCell, 2012
- N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTONature Chemical Biology, 2011
- NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivationOncogene, 2011
- FTO gene variants are strongly associated with type 2 diabetes in South Asian IndiansDiabetologia, 2008
- MTA Is an Arabidopsis Messenger RNA Adenosine Methylase and Interacts with a Homolog of a Sex-Specific Splicing FactorThe Plant Cell, 2008